share_log

CVS Health | 8-K: Current report

CVS Health | 8-K: Current report

西维斯健康 | 8-K:重大事件
美股SEC公告 ·  12/07 05:05

Moomoo AI 已提取核心信息

On December 6, 2024, CVS Health announced the pricing of its cash tender offer for any and all of its 4.100% Senior Notes due 2025. The offer, initiated on December 2, 2024, is open to all registered holders of the notes. The Reference Yield is set at 4.434% with a Total Consideration of $998.22 per $1,000 principal amount.The tender offer is subject to conditions outlined in the Offer to Purchase, with a settlement date expected on December 11, 2024. Holders will receive accrued interest up to the settlement date. Barclays Capital Inc. and Mizuho Securities USA LLC are acting as Dealer Managers.CVS Health reserves the right to amend or terminate the offer. The tender offer is not contingent on a minimum principal amount being tendered but is subject to a financing condition.
On December 6, 2024, CVS Health announced the pricing of its cash tender offer for any and all of its 4.100% Senior Notes due 2025. The offer, initiated on December 2, 2024, is open to all registered holders of the notes. The Reference Yield is set at 4.434% with a Total Consideration of $998.22 per $1,000 principal amount.The tender offer is subject to conditions outlined in the Offer to Purchase, with a settlement date expected on December 11, 2024. Holders will receive accrued interest up to the settlement date. Barclays Capital Inc. and Mizuho Securities USA LLC are acting as Dealer Managers.CVS Health reserves the right to amend or terminate the offer. The tender offer is not contingent on a minimum principal amount being tendered but is subject to a financing condition.
2024年12月6日,CVS Health宣布了其2025年到期的所有4.100%优先票据的现金要约的定价。该要约于2024年12月2日启动,向所有票据的注册持有人开放。参考收益率设定为4.434%,总对价为每1,000美元本金998.22美元。本次要约受收购要约中概述的条件的约束,结算日期预计为2024年12月11日。持有人将在结算日之前获得应计利息。巴克莱资本公司和瑞穗证券美国有限责任公司担任交易商经理。CVS Health保留修改或终止优惠的权利。要约不以投标的最低本金为条件,但受融资条件的约束。
2024年12月6日,CVS Health宣布了其2025年到期的所有4.100%优先票据的现金要约的定价。该要约于2024年12月2日启动,向所有票据的注册持有人开放。参考收益率设定为4.434%,总对价为每1,000美元本金998.22美元。本次要约受收购要约中概述的条件的约束,结算日期预计为2024年12月11日。持有人将在结算日之前获得应计利息。巴克莱资本公司和瑞穗证券美国有限责任公司担任交易商经理。CVS Health保留修改或终止优惠的权利。要约不以投标的最低本金为条件,但受融资条件的约束。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息